The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
The challenges that adolescents and young adults (AYAs) face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, who presented findings on the different outcomes between children and AYAs with acute lymphoblastic leukemia (ALL) at the 59th American Society of Hematology Annual Meeting.
Transcript
How does social support play a role in outcomes among adolescents and young adults with ALL?
It’s not something that we looked at specifically in terms of social support but I think that it really is important when we look at the fact we saw that the duration of treatment, the length of maintenance treatment is really important. We know that these patients are in a really volatile time in their lives. Everyone comes in with a lot of important things happening in their life and that has been disrupted and so others have shown how important social support is and we’ve shown the importance of the duration of treatment. So together I think that just means that making sure we are paying attention to the social needs of these patients is crucial.
What are the unique challenges facing AYAs after treatment?
There are so many challenges that these patients face that are unique and I think that people are really working hard to try to figure out what we can do to help them. But I think the minute they walk into the door, thinking of them as a unique group of patients is the first thing we can do and just recognizing that their lives have been disrupted in a way that younger patients and older patients don’t experience and trying to understand that unique patient’s needs.
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More